Mostrar el registro sencillo del ítem

dc.contributor.authorGuinea, Jesus
dc.contributor.authorPelaez, Teresa
dc.contributor.authorRecio, Sandra
dc.contributor.authorTorres-Narbona, Marta
dc.contributor.authorBouza, Emilio
dc.date.accessioned2024-02-06T11:40:58Z
dc.date.available2024-02-06T11:40:58Z
dc.date.issued2008-04-01
dc.identifier.citationGuinea, J., Peláez, T., Recio, S., Torres-Narbona, M., & Bouza, E. (2008). In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrobial agents and chemotherapy, 52(4), 1396–1400. https://doi.org/10.1128/AAC.01512-07es
dc.identifier.issn0066-4804
dc.identifier.otherhttps://journals.asm.org/journal/aaces
dc.identifier.otherhttps://pubmed.ncbi.nlm.nih.gov/18212101/es
dc.identifier.urihttp://hdl.handle.net/20.500.12020/1249
dc.description.abstractIsavuconazole (BAL4815) is a promising novel broad-spectrum triazole in late-stage clinical development that has proven active in vitro against Aspergillus and Candida species. We compared the in vitro activities of this agent with those of voriconazole and fluconazole by the CLSI (formerly NCCLS) M38-A and M27-A2 procedures against a large collection of 1,007 relevant opportunistic fungi collected from 1986 to 2007: Aspergillus spp. (n = 702), Candida spp. (n = 218), Zygomycetes (n = 45), Scedosporium spp. (n = 22), and Fusarium spp. (n = 20). All Candida isolates were from patients with candidemia. For isavuconazole, these techniques were also compared with the Etest. Isavuconazole and voriconazole had MICs at which 50% and 90% of isolates were inhibited (MIC50 and MIC90), respectively, of 1 and 1  g/ml and 0.5 and 1  g/ml against Aspergillus spp. and of 0.015 and 0.03  g/ml and 0.25 and 0.125  g/ml against Candida spp. (including fluconazole-resistant strains). The MIC50 partial and complete inhibition end points of isavuconazole and voriconazole against the non-Aspergillus molds were as follows: 1 and 2  g/ml and 16 and >16  g/ml against Zygomycetes; 1 and 4  g/ml and 0.25 and 0.5  g/ml against Scedosporium apiospermum; 4 to 16 and >16  g/ml and 4 to 8 and 16 to >16  g/ml (ranges) against Scedosporium prolificans; and 16 and 16  g/ml and 4 and 4 g/ml against Fusarium spp. Isavuconazole showed minimal fungicidal concentrations for 50% and 90% of the isolates of 1 and 1  g/ml against Aspergillus, 16 and >16 g/ml against Candida, and 4 and >16  g/ml against Zygomycetes, respectively, and >16  g/ml against the remaining molds. The Etest proved to be a suitable alternative method for determining the antifungal activities of isavuconazole against Aspergillus and Candida; the Etest results showed 96% and 93% agreement with the results of the CLSI M38-A and M27-A2 methods, respectively.es
dc.language.isoenes
dc.publisherAmerican Society for Microbiologyes
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleIn vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium specieses
dc.typearticlees
dc.identifier.doi10.1128/AAC.01512-07
dc.issue.number4es
dc.journal.titleAntimicrobial Agents and Chemotherapyes
dc.page.initial1396es
dc.page.final1400es
dc.relation.projectIDThis study was partially financed by grants from Basilea Pharmaceutica and from the Spanish Social Security Health Investigation Fund (Fondo de Investigación Sanitaria) FIS PI070198 (Instituto de Salud Carlos III).es
dc.rights.accessRightsembargoedAccesses
dc.subject.areaCiencias Biomédicases
dc.subject.keywordCell-transplant recipientses
dc.subject.keywordAmphotericin Bes
dc.subject.keywordTriazole BAL4815es
dc.subject.keywordDose pharmacokineticses
dc.subject.keywordHealthy-volunteerses
dc.subject.keywordActive componentes
dc.subject.keywordItraconazolees
dc.subject.keywordBAL8557es
dc.subject.keywordProdruges
dc.subject.keywordSusceptibilityes
dc.subject.unesco3201.03 Microbiología Clínicaes
dc.volume.number52es


Ficheros en el ítem

Fichero/sTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional